{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T07:28:12Z","timestamp":1773386892694,"version":"3.50.1"},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"AbbVie Argentina"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Objective<\/jats:title>\n<jats:p>This study aimed to estimate the budget impact of the incorporation of venetoclax for the treatment of patients with Acute Myeloid Leukemia (AML) over 75 years of age or those with comorbidities and contraindications for the use of intensive chemotherapy, from the perspective of the social security and the private third-party payers in Argentina.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>A budget impact model was adapted to estimate the cost difference between the current scenario (azacitidine, decitabine and low doses of cytarabine) and the new scenario (incorporation of venetoclax) for a third-party payer over a time horizon of three years. Input parameters were obtained from a literature review, validated or complemented by expert opinion using a modified Panel Delphi approach. All direct medical costs were estimated by the micro-costing approach and were expressed in US dollars (USD) as of September 2020 (1 USD = 76.18 Argentine pesos).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>For a third-party payer with a cohort of 1,000,000 individuals covered, incorporating venetoclax was associated with an average budget impact per-member per-month (PMPM) of $0.11 USD for the social security sector and $0.07 USD for the private sector. The duration of treatment with venetoclax was the most influential parameter in the budget impact results.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>The introduction of venetoclax was associated with a positive and slight budget impact. These findings are informative to support policy decisions aimed to expand the current treatment landscape of AML.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0295798","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T18:22:47Z","timestamp":1704392567000},"page":"e0295798","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Budget impact analysis of venetoclax for the management of acute myeloid leukemia from the perspective of the social security and the private sector in Argentina"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7684-0880","authenticated-orcid":true,"given":"Alfredo","family":"Palacios","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Espinola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Martin","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1474-1550","authenticated-orcid":true,"given":"Carlos","family":"Rojas-Roque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Marta","family":"Rivas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Kanevski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Morisset","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Augustovski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andres","family":"Pichon-Riviere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariel","family":"Bardach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2024,1,4]]},"reference":[{"key":"pone.0295798.ref001","article-title":"Leucemias Agudas","author":"S Cranco","year":"2017","journal-title":"Sociedad Argentina de Hematolog\u00eda"},{"key":"pone.0295798.ref002","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","article-title":"Cancer statistics, 2012","volume":"62","author":"R Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"pone.0295798.ref003","article-title":"Acute leukemias","author":"E Agriello","year":"2021","journal-title":"Buenos Aires: Sociedad Argentina de Hematolog\u00eda"},{"key":"pone.0295798.ref004","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","article-title":"Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia","volume":"30","author":"HM Kantarjian","year":"2012","journal-title":"J Clin Oncol"},{"key":"pone.0295798.ref005","unstructured":"FDA. FDA approves venetoclax in combination for AML in adults. In: Food and Drug administration [Internet]. Nov 2018 [cited Jun 2019]. https:\/\/www.fda.gov\/drugs\/fda-approves-venetoclax-combination-aml-adults"},{"key":"pone.0295798.ref006","unstructured":"EMA. Venclyxto. In: European Medicines Agency [Internet]. 17 Sep 2018 [cited 8 Mar 2022]. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/venclyxto"},{"key":"pone.0295798.ref007","unstructured":"ANMAT. Aprobaci\u00f3n Venclexta. Agencia Nacional de Medicamentos, Alimentos y Tecnolog\u00eda M\u00e9dica (ANMAT); 2019 Apr. Report No.: Disposici\u00f3n n\u00famero DI-2019-3646-APN-ANMAT#MSYDS. http:\/\/www.anmat.gov.ar\/boletin_anmat\/abril_2019\/Dispo_MSYDS_3646-19.pdf"},{"key":"pone.0295798.ref008","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.leukres.2018.09.001","article-title":"Recently approved therapies in acute myeloid leukemia: A complex treatment landscape","volume":"73","author":"C Talati","year":"2018","journal-title":"Leuk Res"},{"key":"pone.0295798.ref009","unstructured":"CADTH. CADTH reimbursement recommendation: Venetoclax (venclexta). Ottawa: The Canadian Agency for Drugs and Technology in Health (CADTH; 2021 Aug. Report No.: 1. https:\/\/www.cadth.ca\/sites\/default\/files\/DRR\/2021\/PC0238%20Venclexta%20%28AZA%29%20-%20Final%20Rec.pdf"},{"key":"pone.0295798.ref010","unstructured":"NICE. Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable. NICE; 2022 Feb. Report No.: Technology appraisal guidance [TA765]. https:\/\/www.nice.org.uk\/guidance\/ta765\/chapter\/1-Recommendations"},{"key":"pone.0295798.ref011","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s40273-022-01145-7","article-title":"Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective","volume":"40","author":"KW Pratz","year":"2022","journal-title":"Pharmacoeconomics"},{"key":"pone.0295798.ref012","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood-2021-148338","article-title":"Cost Effectiveness Analysis of Venetoclax Plus Azacitidine Versus Azacitidine in Newly Diagnosed Adult Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy from a United States Payer Perspective","volume":"138","author":"KW Pratz","year":"2021","journal-title":"Blood"},{"key":"pone.0295798.ref013","first-page":"980","article-title":"Costs per patient achieving remission with venetoclax-based combinations in newly diagnosed patients with acute myeloid leukemia ineligible for intensive induction chemotherapy","volume":"28","author":"M Choi","year":"2022","journal-title":"J Manag Care Spec Pharm"},{"key":"pone.0295798.ref014","unstructured":"Dorati C, Iusef N, Marin G, Mordujovich P. [Venetoclax for the treatment of acute myeloid leukemia]. Buenos Aires: National Council for the Evaluation of Health Technologies (CONETEC); 2021. https:\/\/www.argentina.gob.ar\/sites\/default\/files\/informe-15-venetoclax_0.pdf"},{"key":"pone.0295798.ref015","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","article-title":"Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force","volume":"17","author":"SD Sullivan","year":"2014","journal-title":"Value Health"},{"key":"pone.0295798.ref016","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1080\/23288604.2018.1477537","article-title":"Making Universal Health Care Effective in Argentina: A Blueprint for Reform","volume":"4","author":"A Rubinstein","year":"2018","journal-title":"Health Syst Reform"},{"key":"pone.0295798.ref017","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12939-020-01168-6","article-title":"Need and inequality in the use of health care services in a fragmented and decentralized health system: evidence for Argentina","volume":"19","author":"A Palacios","year":"2020","journal-title":"Int J Equity Health"},{"key":"pone.0295798.ref018","unstructured":"INDEC. Census 2010. In: National Institute of Statistics and Censuses (INDEC) [Internet]. 2010 [cited 2021]. https:\/\/www.indec.gob.ar\/indec\/web\/Nivel4-Tema-2-41-135"},{"key":"pone.0295798.ref019","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1182\/bloodadvances.2020003902","article-title":"Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia","volume":"5","author":"KK Patel","year":"2021","journal-title":"Blood Adv"},{"key":"pone.0295798.ref020","unstructured":"National Cancer Institute. Surveillance, Epidemiology and End Results Program (SEER). In: Acute Myeloid Leukemia. Incidence Rates [Internet]. 2014 [cited Jun 2019]. https:\/\/seer.cancer.gov\/archive\/csr\/1975_2014\/browse_csr.php?sectionSEL=13&pageSEL=sect_13_table.13.html"},{"key":"pone.0295798.ref021","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"H Dombret","year":"2015","journal-title":"Blood"},{"key":"pone.0295798.ref022","article-title":"Impacto de la respuesta a agentes hipometilantes o quimioterapia intensiva en la sobrevida de pacientes con leucemia mieloide aguda en mayores de 65 a\u00f1os","volume":"23","author":"MJ Mela-Osorio","year":"2019","journal-title":"Hematolog\u00eda"},{"key":"pone.0295798.ref023","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"CD DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"pone.0295798.ref024","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2018-99-117179","article-title":"Venetoclax in Combination with Hypomethylating Agents Induces Rapid, Deep, and Durable Responses in Patients with AML Ineligible for Intensive Therapy","volume":"132","author":"DA Pollyea","year":"2018","journal-title":"Blood"},{"key":"pone.0295798.ref025","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib\/II Study","volume":"37","author":"AH Wei","year":"2019","journal-title":"J Clin Oncol"},{"key":"pone.0295798.ref026","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"AH Wei","year":"2020","journal-title":"Blood"},{"key":"pone.0295798.ref027","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.3109\/10428194.2014.951845","article-title":"Decitabine reduces transfusion dependence in older patients with acute myeloid leukemia: results from a post hoc analysis of a randomized phase III study","volume":"56","author":"J He","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"pone.0295798.ref028","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1200\/JCO.2009.23.8329","article-title":"Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia","volume":"28","author":"P Fenaux","year":"2010","journal-title":"J Clin Oncol"},{"key":"pone.0295798.ref029","unstructured":"Central Bank of Argentina. Exchange rate by date. In: Central Bank of Argentina [Internet]. 2022 [cited 26 Apr 2022]. http:\/\/www.bcra.gov.ar\/PublicacionesEstadisticas\/Cotizaciones_por_fecha_2.asp"},{"key":"pone.0295798.ref030","unstructured":"Grupo Alfa Beta. Precio de medicamentos. In: Grupo Alfa Beta [Internet]. 2020 [cited 16 Mar 2021]. http:\/\/www.alfabeta.net\/precio\/"},{"key":"pone.0295798.ref031","unstructured":"Garfinkel F, M\u00e9ndez Y. Value Chain Reports: Health, Pharmacy and Medical Equipment. Buenos Aires, Argentina: Office for Economic Policy and Development Planning; 2016 Dec. Report No.: 21."},{"key":"pone.0295798.ref032","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/j.vhri.2019.08.042","article-title":"Base de costos unitarios en Salud en Argentina: Una fuente de informaci\u00f3n continuamente actualizada para evaluaciones economicas y analisis de impacto presupuestario en un sistema de Salud fragmentado","volume":"19","author":"A Palacios","year":"2019","journal-title":"Value Health Reg Issues"},{"key":"pone.0295798.ref033","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10198-010-0236-4","article-title":"Practical issues in handling data input and uncertainty in a budget impact analysis","volume":"12","author":"M Nuijten","year":"2011","journal-title":"The European Journal of Health Economics"},{"key":"pone.0295798.ref034","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40273-019-00869-3","article-title":"One-Way Sensitivity Analysis for Probabilistic Cost-Effectiveness Analysis: Conditional Expected Incremental Net Benefit","volume":"38","author":"C McCabe","year":"2020","journal-title":"Pharmacoeconomics"},{"key":"pone.0295798.ref035","unstructured":"PAMI. [Register of affiliates]. In: [PAMI open data portal] [Internet]. 2022 [cited 12 Aug 2022]. https:\/\/datos.pami.org.ar\/dataset\/padron-afiliados"},{"key":"pone.0295798.ref036","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s40258-023-00800-0","article-title":"Budget Impact Analysis of the FreeStyle Libre Flash Continuous Glucose Monitoring System in Patients with Type 1 Diabetes Mellitus and Type 2 Diabetes Mellitus with Multiple Daily Insulin Injections in Argentina","volume":"21","author":"A Palacios","year":"2023","journal-title":"Appl Health Econ Health Policy"},{"key":"pone.0295798.ref037","doi-asserted-by":"crossref","first-page":"e0250711","DOI":"10.1371\/journal.pone.0250711","article-title":"Budget impact analysis of using procalcitonin to optimize antimicrobial treatment for patients with suspected sepsis in the intensive care unit and hospitalized lower respiratory tract infections in Argentina","volume":"16","author":"OU Garay","year":"2021","journal-title":"PLoS One"},{"key":"pone.0295798.ref038","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.vhri.2021.07.004","article-title":"Cost-Effectiveness and Budget Impact Analysis of Primary Screening With Human Papillomavirus Test With Genotyping in Argentina","volume":"26","author":"OU Garay","year":"2021","journal-title":"Value Health Reg Issues"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0295798","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T18:23:17Z","timestamp":1704392597000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0295798"}},"subtitle":[],"editor":[{"given":"Andres Mauricio","family":"Acevedo-Melo","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,1,4]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0295798","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,4]]}}}